A- A A+

Keng-Li Lan (藍耿立)

  • 2875-7270
Keng-Li Lan(藍耿立)

簡介

學歷
  1. 密西根大學 醫學院 藥理博士
  2. 國立陽明大學 醫學院 醫學系 醫學士
經歷 現職:
  1. 2019- 迄今 臺北榮民總醫院 腫瘤醫學部 放射腫瘤科 科主任
  2. - 迄今 臺北榮民總醫院 腫瘤醫學部 放射腫瘤科 主治醫師
  3. - 迄今 國立陽明大學 醫學院 傳醫所 副教授
經歷:
  1. - 國立陽明大學 醫工學院 生物醫學影像暨放射科學系暨研究所 兼任助理教授
  2. - 美國德州大學 安德森癌症中心 兼任講師
  3. - 美國德州大學 安德森癌症中心 博士後研究員
醫療專長
  1. 肺、肝、膽管、胰臟惡性腫瘤治療、分子生物及免疫治療研究、癌症新藥開發
證照
  1. 中華民國放射腫瘤科專科醫師
語言專長
  1. 英文

著作

PubMed

  1. Shen YA, Lan KL, Chang CH, Lin LT, He CL, Chen PH, Lee TW, Lee YJ, Chuang CM.  Intraperitoneal 188Re-Liposome Delivery Switches Ovarian Cancer Metabolism From Glycolysis to Oxidative Phosphorylation and Effectively Controls Ovarian Tumour Growth in Mice. Radiother Oncol 2016 May; 119(2): 282-90. (IF: 4.817; Radiology, Nuclear Medicine & Medical Imaging 10/124; Oncology 39/213)

  2. Li JJ, Lan KL, Chang SF, Chen YF, Tsai WC, Chiang PH, Lin MH, Fischer WB, Shih YS, Yen SH, Liu RS, Tsay YG, Wang HE*, Chang CA*.  Development and Characterization of the Recombinant Human VEGF-EGF Dual-Targeting Fusion Protein as a Drug Delivery System. Bioconjug Chem 2015 Dec; 26(12): 2481-96. (IF: 4.500; Biochemical Research Methods 10/77; Chemistry, Organic 10/59; Chemistry, Multidisciplinary 31/163; Biochemistry & Molecular Biology 64/289)

  3. Chang YJ, Ho CL, Cheng KH, Kuo WI, Lee WC, Lan KL, Chang CH*.  Biodistribution, Pharmacokinetics and Radioimmunotherapy of 188Re-Cetuximab in NCI-H292 Human Lung Tumor-Bearing Nude Mice. Invest New Drugs 2019 Oct; 37(5): 961-72. Epub 2019 Jan. (IF: 3.502; Pharmacology & Pharmacy 64/261; Oncology 92/223)

  4. Kung Y, Lihachev A, Šatkauskas S, Lan KL, Chen WS*.  Electroporation by Concentric-Type Needle Electrodes and Arrays. Bioelectrochemistry 2017 Dec; 118(): 31-7. Epub 2017 Jul. (IF: 3.346; Biology 15/84; Electrochemistry 8/29; Biophysics 21/72; Biochemistry & Molecular Biology 105/286)

  5. Chang CM, Lan KL, Huang WS, Lee YJ, Lee TW, Chang CH, Chuang CM*.  188Re-Liposome Can Induce Mitochondrial Autophagy and Reverse Drug Resistance for Ovarian Cancer: From Bench Evidence to Preliminary Clinical Proof-of-Concept. Int J Mol Sci 2017 Apr; 18(5): E903. (IF: 3.226; Chemistry, Multidisciplinary 54/166; Biochemistry & Molecular Biology 116/286)

  6. Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH*.  Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus. Am J Chin Med 2018 -; 46(4): 835-52. Epub 2018 May. (IF: 3.120; Integrative & Complementary Medicine 3/27; Medicine, General & Internal 31/155)

  7. Wang SJ, Huang WS, Chuang CM, Chang CH, Lee TW, Ting G, Chen MH, Chang PM, Chao TC, Teng HW, Chao Y, Chen YM, Lin TP, Chang YJ, Chen SJ, Huang YR, Lan KL*.  A Phase 0 Study of the Pharmacokinetics, Biodistribution, and Dosimetry of 188Re-Liposome in Patients with Metastatic Tumors. EJNMMI Res 2019 May; 9(1): 46. (IF: 2.630; Radiology, Nuclear Medicine & Medical Imaging 44/129)

  8. Liu YM, Liu YK, Lan KL, Lee YW, Tsai TH*, Chen YJ*.  Medicinal Fungus Antrodia Cinnamomea Inhibits Growth and Cancer Stem Cell Characteristics of Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2013 Mar; 2013(): 569737. (IF: 2.175; Integrative & Complementary Medicine 6/22)

  9. Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH*.  Antiviral Effect of Saikosaponin B2 in Combination with Daclatasvir on NS5A Resistance-Associated Substitutions of Hepatitis C Virus. J Chin Med Assoc 2019 Mar; 82(5): 368-74. (IF: 1.660; Medicine, General & Internal 72/155)

 

電話:(02) 2875-7270
傳真:(02) 2874-9425
e-mail:d-ctc@vghtpe.gov.tw

11217
臺北市北投區石牌路二段201號
交通資訊
維護單位:腫瘤醫學部

目前在線人數: 33  |   今日瀏覽人次: 93  |   總瀏覽人次: 872992  |   本院為無菸醫院  |   我的E政府  |   無障礙標章 A+